$6.8M Investment Pushes Pronota Closer To Development of Diagnostics Pipeline

The Belgian firm will use the funds, secured in the first close of its Series B financing, for the further development of diagnostic programs underway for acute heart failure, sepsis, preeclampsia, and ovarian cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.